QIAGEN forms Lung Cancer Expert Alliance
Key opinion leaders’ expertise to guide design of new gene panels for GeneReader NGS
Key opinion leaders’ expertise to guide design of new gene panels for GeneReader NGS
Actionable Insights Tumor Panel enables monitoring of cancer biomarkers from plasma samples
New innovative ZipChip microfluidic inlet technology designed for fast MS analysis of biomolecules
Future joint collaborations are expected as work continues to unlock the full clinical and research potential of both technologies
Reference data set from Horizon affirms proven accuracy of GeneReader workflow
Studies demonstrate pioneering research possible using ChIP technology
Horizon’s X-MAN cell lines to be made available in conjunction with Ubiquigent’s ubiquitin-related Drug Discovery Services
34-gene panel for assessing risk of 15 inherited cancers among new Quest Vantage™ test services to be highlighted during the 2016 ASCO Annual Meeting
Siemens Healthineers will expand its portfolio with molecular testing related services and technologies for oncology and genomics
Direct comparative studies now possible with a set of cancer-specific genes for DNA from tumor tissue or for circulating tumor DNA from liquid biopsy samples
BioTek Instruments, Inc. presented with Scientists' Choice Award® at AACR
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumor cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis
Agena Bioscience to provide Horizon’s human genomic reference standards to assess quality and performance of oncology-based assays on the MassARRAY System
iPLEX® HS chemistry enables multiplex detection down to 1% allele frequency
New platform enables researchers to rapidly identify cutting-edge anti-cancer drugs
Researchers’ use of ParsortixTM System for studies into multiple cancers confirms the cell separation technology’s ability to harvest viable circulating tumor cells for a broad range of downstream analyses
Agena Bioscience to provide Horizon’s human genomic reference standards to assess quality and performance of oncology-based assays on the MassARRAY System